Skip to navigation Skip to content



First Generic Versions of Aubagio® teriflunomide Now Available

April 17, 2023

On March 13, 2023, several manufacturers launched generic versions of Aubagio® (teriflunomide).
Why This Matters: Having several generic versions available should significantly lower the cost of teriflunomide for many individuals.
  • Teriflunomide is approved for the treatment of adults with relapsing forms of multiple sclerosis including clinically isolated syndrome (an initial neurological episode), relapsing-remitting MS, and active secondary progressive MS.
  • Teriflunomide is an oral tablet that inhibits the function of specific immune cells that have been implicated in MS.
  • Teriflunomide generics:
    • Have the same active ingredient (teriflunomide) as brand name Aubagio.
    • Work in the body the same as Aubagio (teriflunomide) tablets.
    • Have the same safety, efficacy, and side effect profile as Aubagio, and so are considered generic equivalents (“bioequivalent”).
  • Side Effects: The most common adverse reactions reported from clinical trials of Aubagio were headache, diarrhea, nausea, hair thinning or loss, and abnormal liver test results.
  • Potential Risks: Prescribing information cautions that teriflunomide should not be administered in individuals with liver problems or individuals who are pregnant or have childbearing potential who are not using reliable and effective birth control. For additional information, see the Medication Guide.
  • Availability: Generic versions of Aubagio are available by prescription as of March 13, 2023, at specialty pharmacies. A few factors will influence whether individuals will receive a generic or brand-name Aubagio for future prescriptions and how their out-of-pocket (OOP) costs will be impacted, such as:
    • Insurance status
    • Number of generic versions on the market
    • State laws and substitution guidelines
  • Generic manufacturers of teriflunomide include: Zydus, Accord, Dr. Reddy’s, Glenmark, Teva, Camber, Alembic, Apotex, Aurobindo, and Sola.
  • Price: The wholesale acquisition cost of teriflunomide has been reported to be between $32.40 - $2,058.90 per 30-day supply. Aubagio currently costs approximately $9,155.25 per month as of February 15, 2023. The actual cost to an individual will depend on the provisions of their insurance coverage and the degree to which that individual will be eligible for programs designed to assist with out-of-pocket costs.
  • Support Programs: Individuals will need to check with the generic manufacturer of the teriflunomide product they are on to determine if financial assistance programs are available as well as learn about eligibility criteria.
Note: Sanofi, the distributor of brand-name Aubagio, will continue to provide patient support services for all those eligible through MS One to One. This includes financial support – such as co‐pay assistance – for all those eligible through 2023. However, these plans and programs may be changed or modified at any time. It is important to note that MS One to One support services will not be available to individuals on a generic. To connect with the MS One to One service, call 1-855-676-6326.
Aubagio is a registered trademark of Sanofi

About Multiple Sclerosis

Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.

About the National Multiple Sclerosis Society

The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved:, Facebook, X, formerly known as Twitter, Instagram, YouTube or 1-800-344-4867.


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.